Instrument Inactif

Communiqués PHARMING GROUP Euronext Amsterdam

Actions

NL0000377018

Produits pharmaceutiques

Cours en clôture Euronext Amsterdam
- ^EUR	-

14/09	Bourse : Capgemini vend sa division CGS, Euronext reparle consolidation et J&J pourrait céder son orthopédie
14/09	La love story du marché avec l'IA connaît quelques ratés

Communiqués

14/09	FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.	AQ
11/09	FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.	GL
09/09	Pharming Group to participate in September investor conferences	GL
02/09	Pharming N : Millennium International Management LP - Pharming Group N.V. - Leiden	PU
13/08	Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older	GL
04/08	Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference	GL
30/07	Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use	GL
16/07	Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30	GL
08/07	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
03/07	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
03/07	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
05/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja to treat children aged 4 to 11 years with APDS	AQ
04/06	Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS	GL
02/06	Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York	GL
28/05	Pharming Group announces results of 2026 Annual General Meeting of Shareholders	GL
26/05	Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden	PU
22/05	European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union	GL
19/05	Pharming N : Corporate Presentation - May 2026	PU
15/05	Pharming N : 1Q 2026 financial results - Download transcript	PU
08/05	Pharming N : DWS Investment GmbH - Pharming Group N.V. - Leiden	PU
07/05	Pharming N : 1Q 2026 financial results - Download presentation	PU
07/05	Pharming N : 1Q 2026 financial results - Download press release	PU
07/05	Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders	GL
07/05	Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026	GL
23/04	Pharming Group to report first quarter 2026 financial results and provide business update on May 7	GL